WHAT: Details concerning the licensing of rapamycin-related intellectual property developed at the UT Health Science Center San Antonio to an emerging spin-out company, Rapamycin Holdings Inc. Rapamycin, a drug federally approved to suppress organ rejection, continues to be studied for its potential to slow the aging process and its efficacy in treating age-related diseases. The agreement is between STTM, a multi-institution University of Texas technology-management office operated by the Health Science Center, and Rapamycin Holdings.
WHEN: 2 p.m. Friday, Dec. 7
WHERE: Lobby of the South Texas Research Facility at the UT Health Science Center’s Greehey Academic and Research Campus, 8403 Floyd Curl Drive
WHO: Speakers will be Kenneth L. Kalkwarf, D.D.S., M.S., president ad interim of the UT Health Science Center; George Fillis, chief executive officer of Rapamycin Holdings; Arjun Sanga, J.D., assistant vice president for technology transfer at the Health Science Center and executive director of STTM; and San Antonio City Manager Sheryl Sculley.
VISUAL: To close the brief program, stakeholders in rapamycin intellectual property development and commercialization will be invited forward to sign a poster-sized board of a Rapamycin Holdings Inc. logo.